Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC.

Acute heart failure Early post-discharge Management Pre-discharge Prognosis

Journal

European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595

Informations de publication

Date de publication:
07 2023
Historique:
revised: 16 04 2023
received: 14 03 2023
accepted: 30 04 2023
medline: 9 8 2023
pubmed: 14 7 2023
entrez: 14 7 2023
Statut: ppublish

Résumé

Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked increases in death and rehospitalization rates, which then decline exponentially though they remain higher than in patients without a recent hospitalization. Therefore, optimal management of patients with acute heart failure before discharge and in the early post-discharge phase is critical. First, it may prevent rehospitalizations through the early detection and effective treatment of residual or recurrent congestion, the main manifestation of decompensation. Second, initiation at pre-discharge and titration to target doses in the early post-discharge period, of guideline-directed medical therapy may improve both short- and long-term outcomes. Third, in chronic heart failure, medical treatment is often left unchanged, so the acute heart failure hospitalization presents an opportunity for implementation of therapy. The aim of this scientific statement by the Heart Failure Association of the European Society of Cardiology is to summarize recent findings that have implications for clinical management both in the pre-discharge and the early post-discharge phase after a hospitalization for acute heart failure.

Identifiants

pubmed: 37448210
doi: 10.1002/ejhf.2888
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1115-1131

Informations de copyright

© 2023 European Society of Cardiology.

Références

Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009;53:557-573. https://doi.org/10.1016/j.jacc.2008.10.041
Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol. 2015;12:220-229. https://doi.org/10.1038/nrcardio.2015.14
Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, et al.; ESC-EORP-HFA Heart Failure Long-Term Registry Investigators. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21:1338-1352. https://doi.org/10.1002/ejhf.1492
Butt JH, Fosbol EL, Gerds TA, Andersson C, McMurray JJV, Petrie MC, et al. Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: Insights from a nationwide cohort. Eur J Heart Fail. 2020;22:1777-1785. https://doi.org/10.1002/ejhf.1800
Chioncel O, Collins SP, Ambrosy AP, Pang PS, Antohi EL, Iliescu VA, et al. Improving postdischarge outcomes in acute heart failure. Am J Ther. 2018;25:e475-e486. https://doi.org/10.1097/MJT.0000000000000791
Kimmoun A, Takagi K, Gall E, Ishihara S, Hammoum P, El Beze N, et al. Temporal trends in mortality and readmission after acute heart failure: A systematic review and meta-regression in the past four decades. Eur J Heart Fail. 2021;23:420-431. https://doi.org/10.1002/ejhf.2103
Tomasoni D, Lombardi CM, Sbolli M, Cotter G, Metra M. Acute heart failure: More questions than answers. Prog Cardiovasc Dis. 2020;63:599-606. https://doi.org/10.1016/j.pcad.2020.04.007
Hariharaputhiran S, Peng Y, Ngo L, Ali A, Hossain S, Visvanathan R, et al. Long-term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand. Eur J Heart Fail. 2022;24:1519-1528. https://doi.org/10.1002/ejhf.2595
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24:4-131. https://doi.org/10.1002/ejhf.2333
Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: A consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17:544-558. https://doi.org/10.1002/ejhf.289
Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116:1482-1487. https://doi.org/10.1161/CIRCULATIONAHA.107.696906
Rao VN, Murray E, Butler J, Cooper LB, Cox ZL, Fiuzat M, et al. In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2021;78:2004-2012. https://doi.org/10.1016/j.jacc.2021.08.064
Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22:1315-1341. https://doi.org/10.1002/ejhf.1922
Harjola VP, Mebazaa A, Celutkiene J, Bettex D, Bueno H, Chioncel O, et al. Contemporary management of acute right ventricular failure: A statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail. 2016;18:226-241. https://doi.org/10.1002/ejhf.478
Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al.; ESC Heart Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: The ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1242-1254. https://doi.org/10.1002/ejhf.890
Metra M, Teerlink JR. Heart failure. Lancet. 2017;390:1981-1995. https://doi.org/10.1016/S0140-6736(17)31071-1
Tromp J, Bamadhaj S, Cleland JGF, Angermann CE, Dahlstrom U, Ouwerkerk W, et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): A cohort study. Lancet Glob Health. 2020;8:e411-e422. https://doi.org/10.1016/S2214-109X(20)30004-8
O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: An analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2008;156:662-673. https://doi.org/10.1016/j.ahj.2008.04.030
Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18:613-625. https://doi.org/10.1002/ejhf.566
Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154:260-266. https://doi.org/10.1016/j.ahj.2007.01.041
Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al. EuroHeart Failure Survey II (EHFS II): A survey on hospitalized acute heart failure patients: Description of population. Eur Heart J. 2006;27:2725-2736. https://doi.org/10.1093/eurheartj/ehl193
Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, et al.; EVEREST Trial Investigators. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: Findings from the EVEREST trial. Eur Heart J. 2013;34:835-843. https://doi.org/10.1093/eurheartj/ehs444
Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, et al. Assessing and grading congestion in acute heart failure: A scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010;12:423-433. https://doi.org/10.1093/eurjhf/hfq045
Rosano GMC, Allen LA, Abdin A, Lindenfeld J, O'Meara E, Lam CSP, et al. Drug layering in heart failure: Phenotype-guided initiation. JACC Heart Fail. 2021;9:775-783. https://doi.org/10.1016/j.jchf.2021.06.011
Rosano GMC, Moura B, Metra M, Bohm M, Bauersachs J, Ben Gal T, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021;23:872-881. https://doi.org/10.1002/ejhf.2206
Rosano GMC, Vitale C, Adamo M, Metra M. Roadmap for the management of heart failure patients during the vulnerable phase after heart failure hospitalizations: How to implement excellence in clinical practice. J Cardiovasc Med (Hagerstown). 2022;23:149-156. https://doi.org/10.2459/JCM.0000000000001221
Girerd N, Seronde MF, Coiro S, Chouihed T, Bilbault P, Braun F, et al. Integrative assessment of congestion in heart failure throughout the patient journey. JACC Heart Fail. 2018;6:273-285. https://doi.org/10.1016/j.jchf.2017.09.023
Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261:884-888. https://doi.org/10.1001/jama.1989.03420060100040
Van Aelst LNL, Arrigo M, Placido R, Akiyama E, Girerd N, Zannad F, et al. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. Eur J Heart Fail. 2018;20:738-747. https://doi.org/10.1002/ejhf.1050
Rubio-Gracia J, Demissei BG, Ter Maaten JM, Cleland JG, O'Connor CM, Metra M, et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol. 2018;258:185-191. https://doi.org/10.1016/j.ijcard.2018.01.067
Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296:2217-2226. https://doi.org/10.1001/jama.296.18.2217
Cautela J, Tartiere JM, Cohen-Solal A, Bellemain-Appaix A, Theron A, Tibi T, et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. Eur J Heart Fail. 2020;22:1357-1365. https://doi.org/10.1002/ejhf.1835
Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15:1173-1184. https://doi.org/10.1093/eurjhf/hft134
Vader JM, Givertz MM, Starling RC, McNulty SE, Anstrom KJ, Desvigne-Nickens P, et al.; LIFE Investigators. Tolerability of sacubitril/valsartan in patients with advanced heart failure: Analysis of the LIFE trial run-in. JACC Heart Fail. 2022;10:449-456. https://doi.org/10.1016/j.jchf.2022.04.013
Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797-1804. https://doi.org/10.1016/s0735-1097(03)00309-7
Javaloyes P, Miro O, Gil V, Martin-Sanchez FJ, Jacob J, Herrero P, et al.; ICA-SEMES Research Group. Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes. Eur J Heart Fail. 2019;21:1353-1365. https://doi.org/10.1002/ejhf.1502
Rivas-Lasarte M, Maestro A, Fernandez-Martinez J, Lopez-Lopez L, Sole-Gonzalez E, Vives-Borras M, et al. Prevalence and prognostic impact of subclinical pulmonary congestion at discharge in patients with acute heart failure. ESC Heart Fail. 2020;7:2621-2628. https://doi.org/10.1002/ehf2.12842
Bayes-Genis A, Aimo A, Jhund P, Richards M, de Boer RA, Arfsten H, et al. Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24:1767-1777. https://doi.org/10.1002/ejhf.2675
Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21:715-731. https://doi.org/10.1002/ejhf.1494
Bayes-Genis A, Januzzi JL, Richards AM, Arfsten H, de Boer RA, Emdin M, et al. The ‘Peptide for Life’ Initiative: A call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe. Eur J Heart Fail. 2021;23:1432-1436. https://doi.org/10.1002/ejhf.2293
Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168-2174. https://doi.org/10.1161/01.CIR.0000144310.04433.BE
Nunez J, de la Espriella R, Rossignol P, Voors AA, Mullens W, Metra M, et al. Congestion in heart failure: A circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology. Eur J Heart Fail. 2022;24:1751-1766. https://doi.org/10.1002/ejhf.2664
Metra M, Nodari S, Parrinello G, Specchia C, Brentana L, Rocca P, et al. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Eur J Heart Fail. 2007;9:776-786. https://doi.org/10.1016/j.ejheart.2007.05.007
Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al.; RELAX-AHF Investigators. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: Correlation with outcomes. J Am Coll Cardiol. 2013;61:196-206. https://doi.org/10.1016/j.jacc.2012.11.005
O'Brien RJ, Squire IB, Demme B, Davies JE, Ng LL. Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail. 2003;5:499-506. https://doi.org/10.1016/s1388-9842(03)00098-9
Bayes-Genis A, Lopez L, Zapico E, Cotes C, Santalo M, Ordonez-Llanos J, et al. NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J Card Fail. 2005;11:S3-S8. https://doi.org/10.1016/j.cardfail.2005.04.006
Salah K, Kok WE, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, et al. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: A European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF score. Heart. 2014;100:115-125. https://doi.org/10.1136/heartjnl-2013-303632
Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: A randomized clinical trial. JAMA. 2017;318:713-720. https://doi.org/10.1001/jama.2017.10565
Stienen S, Salah K, Moons AH, Bakx AL, van Pol P, Kortz RAM, et al. NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?). Circulation. 2018;137:1671-1683. https://doi.org/10.1161/CIRCULATIONAHA.117.029882
Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial. Lancet. 2022;400:1938-1952. https://doi.org/10.1016/S0140-6736(22)02076-1
Nunez J, Nunez E, Bayes-Genis A, Fonarow GC, Minana G, Bodi V, et al. Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure. Eur Heart J Acute Cardiovasc Care. 2017;6:685-696. https://doi.org/10.1177/2048872616649757
Nunez J, de la Espriella R, Minana G, Santas E, Llacer P, Nunez E, et al. Antigen carbohydrate 125 as a biomarker in heart failure: A narrative review. Eur J Heart Fail. 2021;23:1445-1457. https://doi.org/10.1002/ejhf.2295
Nunez J, Llacer P, Garcia-Blas S, Bonanad C, Ventura S, Nunez JM, et al. CA125-guided diuretic treatment versus usual care in patients with acute heart failure and renal dysfunction. Am J Med. 2020;133:370-80.e4. https://doi.org/10.1016/j.amjmed.2019.07.041
Meijers WC, Bayes-Genis A, Mebazaa A, Bauersachs J, Cleland JGF, Coats AJS, et al. Circulating heart failure biomarkers beyond natriuretic peptides: Review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). Eur J Heart Fail. 2021;23:1610-1632. https://doi.org/10.1002/ejhf.2346
Voors AA, Kremer D, Geven C, Ter Maaten JM, Struck J, Bergmann A, et al. Adrenomedullin in heart failure: Pathophysiology and therapeutic application. Eur J Heart Fail. 2019;21:163-171. https://doi.org/10.1002/ejhf.1366
Pandhi P, Ter Maaten JM, Emmens JE, Struck J, Bergmann A, Cleland JG, et al. Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. Eur J Heart Fail. 2020;22:683-691. https://doi.org/10.1002/ejhf.1693
van der Meer P, Postmus D, Ponikowski P, Cleland JG, O'Connor CM, Cotter G, et al. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol. 2013;61:1973-1981. https://doi.org/10.1016/j.jacc.2012.12.050
Breidthardt T, Weidmann ZM, Twerenbold R, Gantenbein C, Stallone F, Rentsch K, et al. Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function. Eur J Heart Fail. 2017;19:226-236. https://doi.org/10.1002/ejhf.667
Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al.; AFFIRM-AHF Investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396:1895-1904. https://doi.org/10.1016/S0140-6736(20)32339-4
Loncar G, Obradovic D, Thiele H, von Haehling S, Lainscak M. Iron deficiency in heart failure. ESC Heart Fail. 2021;8:2368-2379. https://doi.org/10.1002/ehf2.13265
Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137-155. https://doi.org/10.1002/ejhf.1369
Mullens W, Verbrugge FH, Nijst P, Tang WHW. Renal sodium avidity in heart failure: From pathophysiology to treatment strategies. Eur Heart J. 2017;38:1872-1882. https://doi.org/10.1093/eurheartj/ehx035
Damman K, Ter Maaten JM, Coster JE, Krikken JA, van Deursen VM, Krijnen HK, et al. Clinical importance of urinary sodium excretion in acute heart failure. Eur J Heart Fail. 2020;22:1438-1447. https://doi.org/10.1002/ejhf.1753
Biegus J, Zymlinski R, Testani J, Marciniak D, Zdanowicz A, Jankowska EA, et al. Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients. Eur J Heart Fail. 2021;23:729-739. https://doi.org/10.1002/ejhf.2053
Dauw J, Lelonek M, Zegri-Reiriz I, Paredes-Paucar CP, Zara C, George V, et al. Rationale and design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure study. ESC Heart Fail. 2021;8:4685-4692. https://doi.org/10.1002/ehf2.13666
Ter Maaten JM, Beldhuis IE, van der Meer P, Krikken JA, Coster JE, Nieuwland W, et al. Natriuresis-guided therapy in acute heart failure: Rationale and design of the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial. Eur J Heart Fail. 2022;24:385-392. https://doi.org/10.1002/ejhf.2385
Martens P, Chen HH, Verbrugge FH, Testani JT, Mullens W, Tang WHW. Assessing intrinsic renal sodium avidity in acute heart failure: Implications in predicting and guiding decongestion. Eur J Heart Fail. 2022;24:1978-1987. https://doi.org/10.1002/ejhf.2662
Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22:584-603. https://doi.org/10.1002/ejhf.1697
Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, et al. Renal effects of guideline-directed medical therapies in heart failure: A consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24:603-619. https://doi.org/10.1002/ejhf.2471
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008. https://doi.org/10.1056/NEJMoa1911303
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-1424. https://doi.org/10.1056/NEJMoa2022190
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al.; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-1461. https://doi.org/10.1056/NEJMoa2107038
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al.; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089-1098. https://doi.org/10.1056/NEJMoa2206286
Adamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, et al. Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: Insights from DAPA-HF. Circulation. 2022;146:438-449. https://doi.org/10.1161/CIRCULATIONAHA.121.058910
Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2012;5:54-62. https://doi.org/10.1161/CIRCHEARTFAILURE.111.963413
Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role of the kidney in heart failure. Eur Heart J. 2012;33:2135-2142. https://doi.org/10.1093/eurheartj/ehs205
Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, et al.; Heart Failure Long-Term Registry Investigators Group. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2020;22:1378-1389. https://doi.org/10.1002/ejhf.1793
Nunez J, Bayes-Genis A, Zannad F, Rossignol P, Nunez E, Bodi V, et al. Long-term potassium monitoring and dynamics in heart failure and risk of mortality. Circulation. 2018;137:1320-1330. https://doi.org/10.1161/CIRCULATIONAHA.117.030576
Butler J, Anker SD, Lund LH, Coats AJS, Filippatos G, Siddiqi TJ, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: The DIAMOND trial. Eur Heart J. 2022;43:4362-4373. https://doi.org/10.1093/eurheartj/ehac401
Lancellotti P, Galderisi M, Edvardsen T, Donal E, Goliasch G, Cardim N, et al. Echo-Doppler estimation of left ventricular filling pressure: Results of the multicentre EACVI Euro-Filling study. Eur Heart J Cardiovasc Imaging. 2017;18:961-968. https://doi.org/10.1093/ehjci/jex067
Kajimoto K, Sato N, Takano T; investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) registry. Functional mitral regurgitation at discharge and outcomes in patients hospitalized for acute decompensated heart failure with a preserved or reduced ejection fraction. Eur J Heart Fail. 2016;18:1051-1059. https://doi.org/10.1002/ejhf.562
Goonewardena SN, Gemignani A, Ronan A, Vasaiwala S, Blair J, Brennan JM, et al. Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure. JACC Cardiovasc Imaging. 2008;1:595-601. https://doi.org/10.1016/j.jcmg.2008.06.005
Picano E, Pellikka PA. Ultrasound of extravascular lung water: A new standard for pulmonary congestion. Eur Heart J. 2016;37:2097-2104. https://doi.org/10.1093/eurheartj/ehw164
Platz E, Jhund PS, Girerd N, Pivetta E, McMurray JJV, Peacock WF, et al.; Study Group on Acute Heart Failure of the Acute Cardiovascular Care Association and the Heart Failure Association of the European Society of Cardiology. Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. Eur J Heart Fail. 2019;21:844-851. https://doi.org/10.1002/ejhf.1499
Coiro S, Rossignol P, Ambrosio G, Carluccio E, Alunni G, Murrone A, et al. Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail. 2015;17:1172-1181. https://doi.org/10.1002/ejhf.344
Gargani L, Pang PS, Frassi F, Miglioranza MH, Dini FL, Landi P, et al. Persistent pulmonary congestion before discharge predicts rehospitalization in heart failure: A lung ultrasound study. Cardiovasc Ultrasound. 2015;13:40. https://doi.org/10.1186/s12947-015-0033-4
Platz E, Campbell RT, Claggett B, Lewis EF, Groarke JD, Docherty KF, et al. Lung ultrasound in acute heart failure: Prevalence of pulmonary congestion and short- and long-term outcomes. JACC Heart Fail. 2019;7:849-858. https://doi.org/10.1016/j.jchf.2019.07.008
Platz E, Merz AA, Jhund PS, Vazir A, Campbell R, McMurray JJ. Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: A systematic review. Eur J Heart Fail. 2017;19:1154-1163. https://doi.org/10.1002/ejhf.839
Rivas-Lasarte M, Alvarez-Garcia J, Fernandez-Martinez J, Maestro A, Lopez-Lopez L, Sole-Gonzalez E, et al. Lung ultrasound-guided treatment in ambulatory patients with heart failure: A randomized controlled clinical trial (LUS-HF study). Eur J Heart Fail. 2019;21:1605-1613. https://doi.org/10.1002/ejhf.1604
Mhanna M, Beran A, Nazir S, Sajdeya O, Srour O, Ayesh H, et al. Lung ultrasound-guided management to reduce hospitalization in chronic heart failure: A systematic review and meta-analysis. Heart Fail Rev. 2022;27:821-826. https://doi.org/10.1007/s10741-021-10085-x
Pivetta E, Goffi A, Nazerian P, Castagno D, Tozzetti C, Tizzani P, et al. Lung ultrasound integrated with clinical assessment for the diagnosis of acute decompensated heart failure in the emergency department: A randomized controlled trial. Eur J Heart Fail. 2019;21:754-766. https://doi.org/10.1002/ejhf.1379
Moura B, Aimo A, Al-Mohammad A, Flammer A, Barberis V, Bayes-Genis A, et al. Integration of imaging and circulating biomarkers in heart failure: A consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021;23:1577-1596. https://doi.org/10.1002/ejhf.2339
Seferović PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinković I, et al. The Heart Failure Association Atlas: Heart failure epidemiology and management statistics 2019. Eur J Heart Fail. 2021;23:906-914. https://doi.org/10.1002/ejhf.2143
Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart failure: A position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:1505-1535. https://doi.org/10.1002/ejhf.1236
Patel RB, Fonarow GC, Greene SJ, Zhang S, Alhanti B, DeVore AD, et al. Kidney function and outcomes in patients hospitalized with heart failure. J Am Coll Cardiol. 2021;78:330-343. https://doi.org/10.1016/j.jacc.2021.05.002
Pagnesi M, Lombardi CM, Chiarito M, Stolfo D, Baldetti L, Loiacono F, et al. Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: Results from the HELP-HF registry. Eur J Heart Fail. 2022;24:1493-1503. https://doi.org/10.1002/ejhf.2561
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032. https://doi.org/10.1161/CIR.0000000000001063
Damman K, Kjekshus J, Wikstrand J, Cleland JG, Komajda M, Wedel H, et al. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2016;18:328-336. https://doi.org/10.1002/ejhf.462
Kapelios CJ, Laroche C, Crespo-Leiro MG, Anker SD, Coats AJS, Diaz-Molina B, et al.; Heart Failure Long-Term Registry Investigators Group. Association between loop diuretic dose changes and outcomes in chronic heart failure: Observations from the ESC-EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2020;22:1424-1437. https://doi.org/10.1002/ejhf.1796
Ter Maaten JM, Martens P, Damman K, Dickstein K, Ponikowski P, Lang CC, et al. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clin Res Cardiol. 2020;109:1048-1059. https://doi.org/10.1007/s00392-020-01598-w
Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al.; ADVOR Study Group. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387:1185-1195. https://doi.org/10.1056/NEJMoa2203094
Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome trial. JAMA. 2007;297:1319-1331. https://doi.org/10.1001/jama.297.12.1319
Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, et al.; SECRET of CHF Investigators, Coordinators, and Committee Members. Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol. 2017;69:1409-1419. https://doi.org/10.1016/j.jacc.2016.12.035
Greene SJ, Butler J, Fonarow GC. In-hospital initiation of quadruple medical therapy for heart failure: Making the post-discharge vulnerable phase far less vulnerable. Eur J Heart Fail. 2022;24:227-229. https://doi.org/10.1002/ejhf.2382
Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF registry. J Am Coll Cardiol. 2018;72:351-366. https://doi.org/10.1016/j.jacc.2018.04.070
Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73:2365-2383. https://doi.org/10.1016/j.jacc.2019.02.015
Greene SJ, Ezekowitz JA, Anstrom KJ, Demyanenko V, Givertz MM, Pina IL, et al. Medical therapy during hospitalization for heart failure with reduced ejection fraction: The VICTORIA registry. J Card Fail. 2022;28:1063-1077. https://doi.org/10.1016/j.cardfail.2022.02.011
Carnicelli AP, Lippmann SJ, Greene SJ, Mentz RJ, Greiner MA, Hardy NC, et al. Sacubitril/valsartan initiation and postdischarge adherence among patients hospitalized for heart failure. J Card Fail. 2021;27:826-836. https://doi.org/10.1016/j.cardfail.2021.03.012
Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al.; OPTIMIZE-HF Investigators and Coordinators. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: Results from OPTIMIZE-HF. J Card Fail. 2007;13:722-731. https://doi.org/10.1016/j.cardfail.2007.06.727
Curtis LH, Mi X, Qualls LG, Check DK, Hammill BG, Hammill SC, et al. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am Heart J. 2013;165:979-986.e1. https://doi.org/10.1016/j.ahj.2013.03.007
Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M; IMPACT-HF Investigators and Coordinators. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: Results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol. 2004;43:1534-1541. https://doi.org/10.1016/j.jacc.2003.12.040
Kaplon-Cieslicka A, Benson L, Chioncel O, Crespo-Leiro MG, Coats AJS, Anker SD, et al.; Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2022;24:335-350. https://doi.org/10.1002/ejhf.2408
Greene SJ, Butler J, Fonarow GC. Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed. JAMA Cardiol. 2021;6:743-744. https://doi.org/10.1001/jamacardio.2021.0496
Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS, et al. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2022;24:431-441. https://doi.org/10.1002/ejhf.2397
Gayat E, Arrigo M, Littnerova S, Sato N, Parenica J, Ishihara S, et al. Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: A propensity-score matched study. Eur J Heart Fail. 2018;20:345-354. https://doi.org/10.1002/ejhf.932
Carubelli V, Lombardi C, Specchia C, Peveri G, Oriecuia C, Tomasoni D, et al. Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure. ESC Heart Fail. 2021;8:1944-1953. https://doi.org/10.1002/ehf2.13223
Sharma A, Verma S, Bhatt DL, Connelly KA, Swiggum E, Vaduganathan M, et al. Optimizing foundational therapies in patients with HFrEF: How do we translate these findings into clinical care? JACC Basic Transl Sci. 2022;7:504-517. https://doi.org/10.1016/j.jacbts.2021.10.018
Lam PH, Packer M, Fonarow GC, Faselis C, Allman RM, Morgan CJ, et al. Early effects of starting doses of enalapril in patients with chronic heart failure in the SOLVD Treatment trial. Am J Med. 2020;133:e25-e31. https://doi.org/10.1016/j.amjmed.2019.06.053
Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, et al.; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure: Results from the COPERNICUS study. JAMA. 2003;289:712-718. https://doi.org/10.1001/jama.289.6.712
Bedrouni W, Sharma A, Pitt B, Lam CSP, Ni J, Ferreira JP, et al. Timing of statistical benefit of mineralocorticoid receptor antagonists among patients with heart failure and post-myocardial infarction. Circ Heart Fail. 2022;15:e009295. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009295
Gilstrap LG, Fonarow GC, Desai AS, Liang L, Matsouaka R, DeVore AD, et al. Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction. J Am Heart Assoc. 2017;6:e004675. https://doi.org/10.1161/JAHA.116.004675
Metra M, Torp-Pedersen C, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, et al.; COMET Investigators. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail. 2007;9:901-909. https://doi.org/10.1016/j.ejheart.2007.05.011
Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of beta-blocker withdrawal in acute decompensated heart failure: A systematic review and meta-analysis. JACC Heart Fail. 2015;3:647-653. https://doi.org/10.1016/j.jchf.2015.03.008
Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, et al.; B-CONVINCED Investigators. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009;30:2186-2192. https://doi.org/10.1093/eurheartj/ehp323
Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial. Circulation. 2019;139:2285-2288. https://doi.org/10.1161/CIRCULATIONAHA.118.039331
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al.; PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380:539-548. https://doi.org/10.1056/NEJMoa1812851
Berg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE, et al. Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiol. 2021;6:499-507. https://doi.org/10.1001/jamacardio.2020.7585
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: The EMPEROR-Reduced trial. Circulation. 2021;143:326-336. https://doi.org/10.1161/CIRCULATIONAHA.120.051783
Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. Circulation. 2021;144:1284-1294. https://doi.org/10.1161/CIRCULATIONAHA.121.056824
Kosiborod MN, Angermann CE, Collins SP, Teerlink JR, Ponikowski P, Biegus J, et al. Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: Results from the EMPULSE trial. Circulation. 2022;146:279-288. https://doi.org/10.1161/CIRCULATIONAHA.122.059725
Butler J, Siddiqi TJ, Filippatos G, Ferreira JP, Pocock SJ, Zannad F, et al. Early benefit with empagliflozin in heart failure with preserved ejection fraction: Insights from the EMPEROR-Preserved trial. Eur J Heart Fail. 2022;24:245-248. https://doi.org/10.1002/ejhf.2420
Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22:713-722. https://doi.org/10.1002/ejhf.1713
Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial. Nat Med. 2022;28:568-574. https://doi.org/10.1038/s41591-021-01659-1
Cunningham JW, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, et al. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J Am Coll Cardiol. 2022;80:1302-1310. https://doi.org/10.1016/j.jacc.2022.07.021
Cox ZL, Collins SP, Aaron M, Hernandez GA, Iii ATM, Davidson BT, et al. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. Am Heart J. 2021;232:116-124. https://doi.org/10.1016/j.ahj.2020.10.071
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al.; VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883-1893. https://doi.org/10.1056/NEJMoa1915928
Khan MS, Xu H, Fonarow GC, Lautsch D, Hilkert R, Allen LA, et al. Applicability of vericiguat to patients hospitalized for heart failure in the United States. JACC Heart Fail. 2023;11:211-223. https://doi.org/10.1016/j.jchf.2022.11.007
Bistola V, Simitsis P, Parissis J, Ouwerkerk W, van Veldhuisen DJ, Cleland JG, et al. Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. Eur J Heart Fail. 2021;23:1170-1181. https://doi.org/10.1002/ejhf.2219
Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al.; IRONMAN Study Group. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): An investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400:2199-2209. https://doi.org/10.1016/S0140-6736(22)02083-9
Vitale C, Jankowska E, Hill L, Piepoli M, Doehner W, Anker SD, et al. Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure. Eur J Heart Fail. 2019;21:1299-1305. https://doi.org/10.1002/ejhf.1611
Njoroge JN, Cheema B, Ambrosy AP, Greene SJ, Collins SP, Vaduganathan M, et al. Expanded algorithm for managing patients with acute decompensated heart failure. Heart Fail Rev. 2018;23:597-607. https://doi.org/10.1007/s10741-018-9697-9
Metra M, Gheorghiade M, Bonow RO, Dei Cas L. Postdischarge assessment after a heart failure hospitalization: The next step forward. Circulation. 2010;122:1782-1785. https://doi.org/10.1161/CIRCULATIONAHA.110.982207
Blair JE, Khan S, Konstam MA, Swedberg K, Zannad F, Burnett JC Jr, et al.; EVEREST Investigators. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. Eur Heart J. 2009;30:1666-1673. https://doi.org/10.1093/eurheartj/ehp144
Blair JE, Pang PS, Schrier RW, Metra M, Traver B, Cook T, et al.; EVEREST Investigators. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011;32:2563-2572. https://doi.org/10.1093/eurheartj/ehr238
Dunlay SM, Gheorghiade M, Reid KJ, Allen LA, Chan PS, Hauptman PJ, et al. Critical elements of clinical follow-up after hospital discharge for heart failure: Insights from the EVEREST trial. Eur J Heart Fail. 2010;12:367-374. https://doi.org/10.1093/eurjhf/hfq019
Krumholz HM. Post-hospital syndrome - an acquired, transient condition of generalized risk. N Engl J Med. 2013;368:100-102. https://doi.org/10.1056/NEJMp1212324
Ter Maaten JM, Damman K, Hanberg JS, Givertz MM, Metra M, O'Connor CM, et al. Hypochloremia, diuretic resistance, and outcome in patients with acute heart failure. Circ Heart Fail. 2016;9:e003109. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003109
Pocock SJ, Ferreira JP, Gregson J, Anker SD, Butler J, Filippatos G, et al. Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: The EMPEROR-Reduced trial. Eur Heart J. 2021;42:4455-4464. https://doi.org/10.1093/eurheartj/ehab579
Pocock SJ, Ferreira JP, Packer M, Zannad F, Filippatos G, Kondo T, et al. Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: The EMPEROR-Preserved trial. Eur J Heart Fail. 2022;24:1869-1878. https://doi.org/10.1002/ejhf.2607
Hernandez AF, Greiner MA, Fonarow GC, Hammill BG, Heidenreich PA, Yancy CW, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA. 2010;303:1716-1722. https://doi.org/10.1001/jama.2010.533
DeVore AD, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Lewis EF, et al. Effect of a hospital and postdischarge quality improvement intervention on clinical outcomes and quality of care for patients with heart failure with reduced ejection fraction: The CONNECT-HF randomized clinical trial. JAMA. 2021;326:314-323. https://doi.org/10.1001/jama.2021.8844
Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ, et al.; Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) Investigators. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med. 2008;168:316-324. https://doi.org/10.1001/archinternmed.2007.83
Van Spall HGC, Lee SF, Xie F, Oz UE, Perez R, Mitoff PR, et al. Effect of patient-centered transitional care services on clinical outcomes in patients hospitalized for heart failure: The PACT-HF randomized clinical trial. JAMA. 2019;321:753-761. https://doi.org/10.1001/jama.2019.0710
Li M, Li Y, Meng Q, Li Y, Tian X, Liu R, et al. Effects of nurse-led transitional care interventions for patients with heart failure on healthcare utilization: A meta-analysis of randomized controlled trials. PLoS One. 2021;16:e0261300. https://doi.org/10.1371/journal.pone.0261300
Raat W, Smeets M, Janssens S, Vaes B. Impact of primary care involvement and setting on multidisciplinary heart failure management: A systematic review and meta-analysis. ESC Heart Fail. 2021;8:802-818. https://doi.org/10.1002/ehf2.13152
Lee DS, Straus SE, Farkouh ME, Austin PC, Taljaard M, Chong A, et al.; COACH Trial Investigators. Trial of an intervention to improve acute heart failure outcomes. N Engl J Med. 2023;388:22-32. https://doi.org/10.1056/NEJMoa2211680
Lee DS, Stitt A, Austin PC, Stukel TA, Schull MJ, Chong A, et al. Prediction of heart failure mortality in emergent care: A cohort study. Ann Intern Med. 2012;156:767-775, W-261, W-262. https://doi.org/10.7326/0003-4819-156-11-201206050-00003
Miro O, Rossello X, Platz E, Masip J, Gualandro DM, Peacock WF, et al.; Study Group on Acute Heart Failure of the Acute Cardiovascular Care Association of the European Society of Cardiology. Risk stratification scores for patients with acute heart failure in the emergency department: A systematic review. Eur Heart J Acute Cardiovasc Care. 2020;9:375-398. https://doi.org/10.1177/2048872620930889
Lee DS, Stukel TA, Austin PC, Alter DA, Schull MJ, You JJ, et al. Improved outcomes with early collaborative care of ambulatory heart failure patients discharged from the emergency department. Circulation. 2010;122:1806-1814. https://doi.org/10.1161/CIRCULATIONAHA.110.940262
Van Spall HGC, Rahman T, Mytton O, Ramasundarahettige C, Ibrahim Q, Kabali C, et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: A systematic review and network meta-analysis. Eur J Heart Fail. 2017;19:1427-1443. https://doi.org/10.1002/ejhf.765
Thodi M, Bistola V, Lambrinou E, Keramida K, Nikolopoulos P, Parissis J, et al. A randomized trial of a nurse-led educational intervention in patients with heart failure and their caregivers: Impact on caregiver outcomes. Eur J Cardiovasc Nurs. https://doi.org/10.1093/eurjcn/zvac118. Published online ahead of print 13/12/22
Liljeroos M, Stromberg A. Introducing nurse-led heart failure clinics in Swedish primary care settings. Eur J Heart Fail. 2019;21:103-109. https://doi.org/10.1002/ejhf.1329
Jonkman NH, Westland H, Groenwold RH, Agren S, Anguita M, Blue L, et al. What are effective program characteristics of self-management interventions in patients with heart failure? An individual patient data meta-analysis. J Card Fail. 2016;22:861-871. https://doi.org/10.1016/j.cardfail.2016.06.422
Koelling TM, Johnson ML, Cody RJ, Aaronson KD. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation. 2005;111:179-185. https://doi.org/10.1161/01.CIR.0000151811.53450.B8
Oh S, Choi H, Oh EG, Lee JY. Effectiveness of discharge education using teach-back method on readmission among heart failure patients: A systematic review and meta-analysis. Patient Educ Couns. 2023;107:107559. https://doi.org/10.1016/j.pec.2022.11.001
Brahmbhatt DH, Cowie MR. Remote management of heart failure: An overview of telemonitoring technologies. Card Fail Rev. 2019;5:86-92. https://doi.org/10.15420/cfr.2019.5.3
Cleland JGF, Clark RA, Pellicori P, Inglis SC. Caring for people with heart failure and many other medical problems through and beyond the COVID-19 pandemic: The advantages of universal access to home telemonitoring. Eur J Heart Fail. 2020;22:995-998. https://doi.org/10.1002/ejhf.1864
Task Force for the management of COVID-19 of the European Society of Cardiology. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: Part 2 - care pathways, treatment, and follow-up. Eur Heart J. 2022;43:1059-1103. https://doi.org/10.1093/eurheartj/ehab697
Frederix I, Caiani EG, Dendale P, Anker S, Bax J, Bohm A, et al. ESC e-Cardiology Working Group Position Paper: Overcoming challenges in digital health implementation in cardiovascular medicine. Eur J Prev Cardiol. 2019;26:1166-1177. https://doi.org/10.1177/2047487319832394
Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z, et al. Telemonitoring in patients with heart failure. N Engl J Med. 2010;363:2301-2309. https://doi.org/10.1056/NEJMoa1010029
Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Bohm M, et al.; Telemedical Interventional Monitoring in Heart Failure Investigators. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: The Telemedical Interventional Monitoring in Heart Failure study. Circulation. 2011;123:1873-1880. https://doi.org/10.1161/CIRCULATIONAHA.111.018473
Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Winkler S, et al. Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: Study design and description of the intervention. Eur J Heart Fail. 2018;20:1485-1493. https://doi.org/10.1002/ejhf.1300
Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan BA, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): A randomised, controlled, parallel-group, unmasked trial. Lancet. 2018;392:1047-1057. https://doi.org/10.1016/S0140-6736(18)31880-4
Cleland JG, Louis AA, Rigby AS, Janssens U, Balk AH; TEN-HMS Investigators. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: The Trans-European Network-Home-Care Management System (TEN-HMS) study. J Am Coll Cardiol. 2005;45:1654-1664. https://doi.org/10.1016/j.jacc.2005.01.050
Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, et al. Transition from chronic compensated to acute decompensated heart failure: Pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118:1433-1441. https://doi.org/10.1161/CIRCULATIONAHA.108.783910
Conraads VM, Tavazzi L, Santini M, Oliva F, Gerritse B, Yu CM, et al. Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: The SENSE-HF trial. Eur Heart J. 2011;32:2266-2273. https://doi.org/10.1093/eurheartj/ehr050
Landolina M, Perego GB, Lunati M, Curnis A, Guenzati G, Vicentini A, et al. Remote monitoring reduces healthcare use and improves quality of care in heart failure patients with implantable defibrillators: The Evolution of Management Strategies of Heart Failure Patients With Implantable Defibrillators (EVOLVO) study. Circulation. 2012;125:2985-2992. https://doi.org/10.1161/CIRCULATIONAHA.111.088971
Shochat MK, Shotan A, Blondheim DS, Kazatsker M, Dahan I, Asif A, et al. Non-invasive lung IMPEDANCE-guided preemptive treatment in chronic heart failure patients: A randomized controlled trial (IMPEDANCE-HF trial). J Card Fail. 2016;22:713-722. https://doi.org/10.1016/j.cardfail.2016.03.015
Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al.; CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. Lancet. 2011;377:658-666. https://doi.org/10.1016/S0140-6736(11)60101-3
Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, et al.; CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: Complete follow-up results from the CHAMPION randomised trial. Lancet. 2016;387:453-461. https://doi.org/10.1016/S0140-6736(15)00723-0
Angermann CE, Assmus B, Anker SD, Asselbergs FW, Brachmann J, Brett ME, et al.; MEMS-HF Investigators. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: The CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). Eur J Heart Fail. 2020;22:1891-1901. https://doi.org/10.1002/ejhf.1943
Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): A randomised controlled trial. Lancet. 2021;398:991-1001. https://doi.org/10.1016/S0140-6736(21)01754-2
Mullens W, Sharif F, Dupont M, Rothman AMK, Wijns W. Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: Results of the SIRONA first-in-human study. Eur J Heart Fail. 2020;22:1912-1919. https://doi.org/10.1002/ejhf.1870
Dauw J, Sokolski M, Middleton JT, Nijst P, Dupont M, Forouzan O, et al. Ambulatory haemodynamic-guided management reduces heart failure hospitalizations in a multicentre European heart failure cohort. ESC Heart Fail. 2022;9:3858-3867. https://doi.org/10.1002/ehf2.14056
Edelmann F, Gelbrich G, Dungen HD, Frohling S, Wachter R, Stahrenberg R, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: Results of the Ex-DHF (Exercise Training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol. 2011;58:1780-1791. https://doi.org/10.1016/j.jacc.2011.06.054
Nolte K, Herrmann-Lingen C, Wachter R, Gelbrich G, Dungen HD, Duvinage A, et al. Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: The Ex-DHF-P trial. Eur J Prev Cardiol. 2015;22:582-593. https://doi.org/10.1177/2047487314526071
Flynn KE, Pina IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, et al.; HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1451-1459. https://doi.org/10.1001/jama.2009.457
Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, et al.; ExTraMATCH II Collaboration. Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: Individual participant meta-analysis. J Am Coll Cardiol. 2019;73:1430-1443. https://doi.org/10.1016/j.jacc.2018.12.072
Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, et al.; ExTraMATCH II Collaboration. Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: An individual patient data meta-analysis of randomised trials. Eur J Heart Fail. 2018;20:1735-1743. https://doi.org/10.1002/ejhf.1311
Buckley BJR, Harrison SL, Fazio-Eynullayeva E, Underhill P, Sankaranarayanan R, Wright DJ, et al. Cardiac rehabilitation and all-cause mortality in patients with heart failure: A retrospective cohort study. Eur J Prev Cardiol. 2021;28:1704-1710. https://doi.org/10.1093/eurjpc/zwab035
Ramachandran HJ, Jiang Y, Tam WWS, Yeo TJ, Wang W. Effectiveness of home-based cardiac telerehabilitation as an alternative to phase 2 cardiac rehabilitation of coronary heart disease: A systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29:1017-1043. https://doi.org/10.1093/eurjpc/zwab106
Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, et al. Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: Why and how: A position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2022;29:230-245. https://doi.org/10.1093/eurjpc/zwab007

Auteurs

Marco Metra (M)

Cardiology and Cardiac Catheterization Laboratory, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Marianna Adamo (M)

Cardiology and Cardiac Catheterization Laboratory, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Daniela Tomasoni (D)

Cardiology and Cardiac Catheterization Laboratory, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Alexandre Mebazaa (A)

AP-HP Department of Anesthesia and Critical Care, Hôpital Lariboisière, Université Paris Cité, Inserm MASCOT, Paris, France.

Antoni Bayes-Genis (A)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Badalona, Spain.
Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBERCV, Instituto de Salud Carlos III, Madrid, Spain.

Magdy Abdelhamid (M)

Faculty of Medicine, Cairo University, Giza, Egypt.

Stamatis Adamopoulos (S)

Second Department of Cardiovascular Medicine, Onassis Cardiac Surgery Center, Athens, Greece.

Stefan D Anker (SD)

Department of Cardiology (CVK); and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.

Johann Bauersachs (J)

Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

Yuri Belenkov (Y)

Lomonosv Moscow State University, Moscow, Russia.

Michael Böhm (M)

Saarland University Hospital, Homburg/Saar, Germany.

Tuvia Ben Gal (TB)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Javed Butler (J)

Baylor Scott and White Research Institute, Dallas, TX, USA.
Department of Medicine, University of Mississippi, Jackson, MS, USA.

Alain Cohen-Solal (A)

Inserm 942 MASCOT, Université de Paris, AP-HP, Hopital Lariboisière, Paris, France.

Gerasimos Filippatos (G)

Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Finn Gustafsson (F)

Rigshospitalet-Copenhagen University Hospital, Heart Centre, Department of Cardiology, Copenhagen, Denmark.

Loreena Hill (L)

Queen's University Belfast, Belfast, UK.

Tiny Jaarsma (T)

Linkoping University, Linkoping, Sweden.

Ewa A Jankowska (EA)

Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.

Mitja Lainscak (M)

Division of Cardiology, General Hospital Murska Sobota, Murska Sobota, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Yuri Lopatin (Y)

Volgograd State Medical University, Volgograd, Russia.

Lars H Lund (LH)

Department of Medicine, Karolinska Institutet, and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.

Theresa McDonagh (T)

Department of Cardiovascular Science, Faculty of Life Science and Medicine, King's College London, London, UK.

Davor Milicic (D)

Massachusetts General Hospital and Baim Institute for Clinical Research, Boston, MA, USA.

Brenda Moura (B)

Faculty of Medicine, University of Porto, Porto, Portugal.
Cardiology Department, Porto Armed Forces Hospital, Porto, Portugal.

Wilfried Mullens (W)

Hospital Oost-Limburg, Genk, Belgium.

Massimo Piepoli (M)

Clinical Cardiology, IRCCS Policlinico San Donato, Milan, Italy.
Department of Biomedical Science for Health, University of Milan, Milan, Italy.

Marija Polovina (M)

Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Piotr Ponikowski (P)

Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.

Amina Rakisheva (A)

Scientific Research Institute of Cardiology and Internal Medicine, Almaty, Kazakhstan.

Arsen Ristic (A)

School of Medicine, University of Belgrade, Belgrade, Serbia.

Gianluigi Savarese (G)

Department of Medicine, Karolinska Institutet, and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.

Petar Seferovic (P)

Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Serbian Academy of Sciences and Arts, Belgrade, Serbia.

Rajan Sharma (R)

St. George's Hospitals NHS Trust University of London, London, UK.

Thomas Thum (T)

Institute of Molecular and Translational Therapeutic Strategies (IMTTS) and Rebirth Center for Translational Regenerative Therapies, Hannover Medical School, Hannover, Germany.
Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany.

Carlo G Tocchetti (CG)

Cardio-Oncology Unit, Department of Translational Medical Sciences, Center for Basic and Clinical Immunology Research (CISI), Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, Italy.

Sophie Van Linthout (S)

German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany.
Berlin Institute of Health (BIH) at Charité-Universitätmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany.

Cristiana Vitale (C)

Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele Pisana, Rome, Italy.

Stephan Von Haehling (S)

Department of Cardiology and Pneumology, University Medical Center Goettingen, Georg-August University, Goettingen, Germany.
German Center for Cardiovascular Research (DZHK), partner site Goettingen, Goettingen, Germany.

Maurizio Volterrani (M)

Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele Pisana, Rome, Italy.

Andrew J S Coats (AJS)

University of Warwick Coventry, Coventry, UK.

Ovidiu Chioncel (O)

Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', University of Medicine Carol Davila, Bucharest, Romania.

Giuseppe Rosano (G)

St. George's Hospitals NHS Trust University of London, London, UK.
Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele Pisana, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH